Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES)
Authors' conclusion
Of romosozumab-treated patients with 15 months follow-up data, most were assumed to continue romosozumab for 11-15 months when treatment transition was recorded.
Study context
- Population
- Females aged ≥ 50 receiving osteoporosis medication in Denmark, September 2020 - October 2023
- Participants
- 149,395 females
- Exposure
- Romosozumab vs other osteoporosis medications
- Cohort 1n = 622
- Cohort 2n = 29,021
- Cohort 3n = 119,752
- Outcome
- Patient and prescriber characteristics and romosozumab treatment patterns
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
| Group | Value | Osteoporosis treatment-naïve |
|---|---|---|
| Cohort 1 | 44.5% | 277 (44.5%) |
Cohort 1
Value44.5%
Osteoporosis treatment-naïve277 (44.5%)
- Median duration from romosozumab initiation to recorded treatment transition (days)
- 350
- Most transitioned between 11-15 months; transition to zoledronate
- 53.5%
- Transition to alendronate
- 18.9%
- Transition to denosumab
- 13.5%
Observational data: associations, not effects.
Original publication
Treatment patterns of romosozumab in postmenopausal women with severe osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES). Osteoporos Int. Published 19 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →